Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer

Published:2018-06 Issue: Volume:67 Page:63-70
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Cejalvo Juan Miguel,Pascual Tomás,Fernández-Martínez Aranzazu,Brasó-Maristany Fara,Gomis Roger R.,Perou Charles M.,Muñoz Montserrat,Prat Aleix

Funder

Susan Komen Foundation

Spanish Ministerio de Economia y Competitividad

FEDER

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference74 articles.

1. Deconstructing the molecular portraits of breast cancer;Prat;Mol Oncol,2011

2. Clinical implications of the intrinsic molecular subtypes of breast cancer;Prat;Breast,2015

3. Practical implications of gene-expression-based assays for breast oncologists;Prat;Nat Rev Clin Oncol,2011

4. Comprehensive molecular portraits of human breast tumours;Network;Nature,2012

5. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer;Prat;Breast Cancer Res,2010

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?;ESMO Open;2024-09

2. Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer;JNCI: Journal of the National Cancer Institute;2024-07-31

3. Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer;Scientific Reports;2024-07-11

4. Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review;Journal of Modern Oncology;2024-07-03

5. Computational Model Predicts Patient Outcomes in Luminal B Breast Cancer Treated with Endocrine Therapy and CDK4/6 Inhibition;Clinical Cancer Research;2024-06-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3